Novel Biomarkers Distinguishing Active Tuberculosis from Latent Infection Identified by Gene Expression Profile of Peripheral Blood Mononuclear Cells by Lu, Chanyi et al.
Novel Biomarkers Distinguishing Active Tuberculosis
from Latent Infection Identified by Gene Expression
Profile of Peripheral Blood Mononuclear Cells
Chanyi Lu
1,2, Jing Wu
1,2, Honghai Wang
2, Sen Wang
1, Ni Diao
1, Feifei Wang
1, Yan Gao
1, Jiazhen Chen
1,
Lingyun Shao
1, Xinhua Weng
1, Ying Zhang
1,3*, Wenhong Zhang
1,4*
1Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China, 2State Key Laboratory of Genetic Engineering(SKLGE), Institute of Genetics,
School of Life Sciences, Fudan University, Shanghai, China, 3Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins
University, Baltimore, Maryland, United States of America, 4Institutes of Biomedical Sciences, Fudan University, Shanghai, China
Abstract
Background: Humans infected with Mycobacterium tuberculosis (MTB) can delete the pathogen or otherwise become latent
infection or active disease. However, the factors influencing the pathogen clearance and disease progression from latent
infection are poorly understood. This study attempted to use a genome-wide transcriptome approach to identify immune
factors associated with MTB infection and novel biomarkers that can distinguish active disease from latent infection.
Methodology/Principal Findings: Using microarray analysis, we comprehensively determined the transcriptional difference
in purified protein derivative (PPD) stimulated peripheral blood mononuclear cells (PBMCs) in 12 individuals divided into
three groups: TB patients (TB), latent TB infection individuals (LTBI) and healthy controls (HC) (n=4 per group). A
transcriptional profiling of 506 differentially expressed genes could correctly group study individuals into three clusters.
Moreover, 55- and 229-transcript signatures for tuberculosis infection (TB&LTBI) and active disease (TB) were identified,
respectively. The validation study by quantitative real-time PCR (qPCR) performed in 83 individuals confirmed the
expression patterns of 81% of the microarray identified genes. Decision tree analysis indicated that three genes of CXCL10,
ATP10A and TLR6 could differentiate TB from LTBI subjects. Additional validation was performed to assess the diagnostic
ability of the three biomarkers within 36 subjects, which yielded a sensitivity of 71% and specificity of 89%.
Conclusions/Significance: The transcription profiles of PBMCs induced by PPD identified distinctive gene expression
patterns associated with different infectious status and provided new insights into human immune responses to MTB.
Furthermore, this study indicated that a combination of CXCL10, ATP10A and TLR6 could be used as novel biomarkers for
the discrimination of TB from LTBI.
Citation: Lu C, Wu J, Wang H, Wang S, Diao N, et al. (2011) Novel Biomarkers Distinguishing Active Tuberculosis from Latent Infection Identified by Gene
Expression Profile of Peripheral Blood Mononuclear Cells. PLoS ONE 6(8): e24290. doi:10.1371/journal.pone.0024290
Editor: Niyaz Ahmed, University of Hyderabad, India
Received April 11, 2011; Accepted August 4, 2011; Published August 31, 2011
Copyright:  2011 Lu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported in part by research grants from the Shanghai Science and Technology Development Funds (10XD1400900, 10QA1401100)
and National Natural Science Foundation of China (30901277), Key Technologies Research and Development Program for Infectious Diseases of China
(2008ZX10003003, 2009ZX10004-104) and the Key Project of Science and Technology of Shanghai (10411955000). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: zhangwenhong@fudan.edu.cn (WZ); pharmlife2002@yahoo.com (YZ)
Introduction
Tuberculosis remains a leading infectious disease worldwide.
Therewere9.4million new TB cases with 1.6million deathsin2009
and about 2 billion people were latently infected with MTB [1,2].
Most people infected with MTB remain asymptomatic, termed
LTBI, presumably due to human protective immune response [3,4].
In the United States, 20–30% of close contacts have latent infection
[5,6], while an estimated 15% of Chinese population have latent
infection identifiedbyT-cell-based gammainterferon (IFN-c) release
assays (IGRAs) [7]. 10% of LTBI individuals will progress to active
TB in their lifetime [1]. However, immunological determinants of
host-pathogen interactions resulting in disease progression, latency
or clearance remain poorly understood. Although human immune
factors are known to play a pivotal role in the control of infection
[8,9,10], more immunological network signatures with respect to
disease, MTB infection or clearance need to be defined [11,12].
Although QuantiFERON-TB Gold In-tube (Cellestis, Victoria,
Australia) and T-SPOT.TB (Oxford Immunotech, UK) based on
ESAT-6 and CFP-10 are capable of distinguishing individuals
vaccinated with BCG from MTB infection [13,14], these assays
could not discriminate active TB disease from LTBI [15].
Apparently, MTB-specific IFN-c release is not sufficient to
represent the comprehensive immunological changes stimulated
by MTB. It is generally accepted that both innate and acquired
immune responses play an important role in controlling MTB
infection [8,9]. Nevertheless, when conditions such as HIV
infection,immunosuppressiveagentsorstressescompromisenormal
immune function, latent infection can be reactivated to clinical
disease [16,17,18].
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chemokine responses to MTB-specific antigens that are involved in
the progression from latent infection to active disease [19,20,21].
However, these studies revealed only limited insight into human
resistance or susceptibility to MTB infection. More recently,
genome-wide transcriptome analyses have been widely used to
explore the complex interaction between human and bacteria
[22,23,24,25]. However, results varied due to diverse genetic
background of the study population and the inherent complexity
of the disease process and the immune response. In addition, most
of these microarray studies used the peripheral whole blood
without stimulation by MTB-specific antigens, which may lead to
interference with other conditions than TB and skew the resulting
TB-associated transcription profiles and candidate genes used for
discriminating TB from LTBI.
To better understand the immunologic characteristics of
different status of TB infection and to identify potential immune
biomarkers that could discriminate active disease from latent
infection, we performed genome-wide transcription analysis of
PPD-stimulated PBMCs from subjects with TB, LTBI and HC,
and identified unique transcript profiles in individuals with
tuberculosis infection and active disease. The identified signatures
will not only provide new insight into the immune mechanisms
involved in MTB infection but also furnish new biomarkers which
may distinguish active TB patients from LTBI individuals.
Results
Identification of differences in gene expression profiling
of PBMCs in response to PPD in TB, LTBI, and HC groups
Based on our hypothesis that PBMCs from individuals with
different MTB infectious status could exhibit distinct transcription
profiles when stimulated by PPD, we isolated PBMCs from 12
subjects (TB=4, LTBI=4, HC=4) and then stimulated them
with or without PPD for 4 hours. Using Whole Human Genome
Oligo Microarray (Agilent), we determined the fold changes of
gene expression levels regulated by PPD in the PBMCs. The ratios
of the fold changes were compared among three pair-wise
comparisons (LTBI vs. HC; TB vs. LTBI; and TB vs. HC).
Transcriptional profiles of LTBI and HC groups exhibited
relatively similar patterns with 94 differentially expressed genes
being observed, while TB groups exhibited much more differen-
tially expressed genes when compared with LTBI and HC groups
(n=239 and 286, respectively; Table 1). Differentially expressed
genes in these three pair-wise comparisons with ratio .4 were
present in Table 2, which were largely dominated by genes
encoding chemokines, cytokines and receptors.
The gene ontology (GO) analysis of differentially expressed
genes revealed that genes associated with extracellular component
and movement in response to external stimulus were significantly
enriched in the comparison of LTBI and HC. Meanwhile, gene
categories of extracellular region part, receptor binding, signal
transduction, response to stimulus, regulation of immune system
process and cell communication were enriched between TB and
HC. However, only one GO term with function of response to
external stimulus was identified in the comparison between TB
and LTBI groups (Table S1).
Venn diagram of these differentially expressed genes in three
pair-wise comparisons showed that most genes were unique in
each pair-wise comparison, with 67% (63/94) in LTBI vs. HC,
Table 1. Gene expression ratios among different groups and
their comparisons in PPD-stimulated PBMCs by microarray
analysis with P value ,0.05.
ratio.88 .ratio.44 .ratio.2
Pair-wise comparisons
LTBI/HC 2 3 26
HC/LTBI 0 0 63
TB/LTBI 0 3 136
LTBI/TB 1 4 142
TB/HC 9 7 98
HC/TB 1 0 124
Different infectious status
TB&LTBI/HC 2 7 26
HC/TB&LTBI 0 0 40
TB/LTBI&HC 0 9 101
LTBI&HC/TB 1 1 137
doi:10.1371/journal.pone.0024290.t001 Table 2. Significantly regulated genes in PPD-stimulated
PBMCs in pair-wise comparisons with ratio .4.
GeneSymbol Means Ratio Regulation t-test
LTBI/HC LTBI HC P value
IL2 72.38 5.65 12.81 up 0.0117
CXCL9 6.58 1.32 4.97 up 0.0284
IFNG 7.09 1.76 4.03 up 0.0002
BATF2 3.39 0.84 4.01 up 0.0201
TB/LTBI TB LTBI P value
BX090755 0.10 1.11 11.51 down 0.0437
DB513559 0.09 0.45 5.29 down 0.0239
SDS 0.07 0.31 4.66 down 0.0225
A_24_P931568 0.88 3.93 4.49 down 0.0010
WDR69 0.19 0.83 4.25 down 0.0139
MYO1B 4.75 1.12 4.25 up 0.0014
HMGA2 4.97 1.20 4.13 up 0.0054
AF113012 1.74 0.43 4.02 up 0.0202
TB/HC TB HC P value
IL2 128.76 5.65 22.80 up 0.0076
IFNG 24.46 1.76 13.92 up 0.0002
CXCL9 16.42 1.32 12.41 up 0.0095
CXCL11 6.64 0.65 10.21 up 0.0383
CXCL10 7.48 0.77 9.69 up 0.0136
BX090755 0.10 0.86 8.91 down 0.0342
CCL8 6.22 0.70 8.90 up 0.0259
UBD 8.01 0.96 8.31 up 0.0285
RSPO3 1.76 0.24 7.19 up 0.0275
BATF2 4.85 0.84 5.74 up 0.0160
Q9BVX4 0.48 0.09 5.62 up 0.0075
SLAMF8 2.83 0.54 5.25 up 0.0195
IL22 4.75 1.14 4.19 up 0.0458
MUCL1 7.00 1.68 4.17 up 0.0069
PDGFRA 5.55 1.36 4.08 up 0.0205
doi:10.1371/journal.pone.0024290.t002
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(Figure 1A). After deducting the number of shared genes among
the comparisons, a total of 506 differentially expressed genes were
identified. Comparisons of TB with the other two groups (TB vs.
LTBI and TB vs. HC) shared the biggest number of differentially
expressed genes (n=82), which were mainly involved in pathways
of signaling molecules and interaction, cancers, signal transduc-
tion, and cell communication. Among the 506 genes, IFN-c was
shared in all three pair-wise comparisons (Figure 1A).
In order to determine whether the expression patterns of this
506-transcript profile above could indeed reflect the different
status of MTB infection, unsupervised hierarchical cluster analysis
was performed. It showed that 12 individuals were successfully
clustered into three groups, and each group matched exactly to the
corresponding grouping of TB, LTBI and HC (Figure 2).
Unique transcript profiles of PBMCs in the individuals
with tuberculosis infection and active disease
We next focused our analysis on identifying unique gene
expression signatures of tuberculosis infection (TB&LTBI) and
active disease (TB). We compared gene expressions of PBMCs
following PPD stimulation between (1) TB&LTBI groups and HC
group (TB&LTBI/HC) according to whether individuals was
infected by MTB or not and (2) TB group and LTBI&HC groups
(TB/LTBI&HC) according to whether active disease was clinically
developed or not.
The results showed that 75 differentially expressed genes were
identified in TB&LTBI/HC, and 249 genes were found in TB/
LTBI&HC (Table 1). Most of the genes with ratio .4 belonged to
signaling molecules and immune response molecules (Table 3). As
shown in Figure 1B, 20 differentially expressed genes were shared
Figure 1. Venn diagram of differentially expressed genes in PBMCs samples following PPD stimulation with P value ,0.05 by
Student’s t-test and fold change .2.0 from: A, Pair-wise comparisons between three study groups (LTBI vs. HC; TB vs. HC; TB vs.
LTBI); B, Transcription profiles of tuberculosis infection and active disease (TB&LTBI group vs. HC group; TB group vs. LTBI&HC
group). The total numbers of genes in panel A and B were 506 and 304 respectively.
doi:10.1371/journal.pone.0024290.g001
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(229/249) genes were specifically present in each comparison,
respectively. Thus, 55 and 229 genes correspondingly stood for the
specific transcript profiles associated with tuberculosis infection
(TB&LTBI)andactivedisease(TB).Functionalannotationofthe55
genes in tuberculosis infection profile revealed that gene cluster of
regulation of T cell homeostatic proliferation was significantly
enriched with increased expression levels in TB&LTBI compared
Figure 2. Unsupervised hierarchical cluster analysis of 506 differentially expressed genes in the pair-wise comparisons. There are 4
samples in each group. Pseudocolors indicate differential expression (red, up-regulation; green, down-regulation; black, no change in expression).
doi:10.1371/journal.pone.0024290.g002
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response to external stimulus were enriched in active disease profile
(corrected P value ,0.05; Table S1).
Validation of differentially expressed genes in
independent sample set by qPCR
In order to validate the microarray results, we selected 30
differentially expressed genes from three pair-wise comparisons
and 22 genes specific for tuberculosis infection and active disease
to carry out the qPCR study using the same samples in the
microarray experiment. A high concordance of qPCR results with
microarray data was found (94%), which validates the reliability of
the microarray study.
We subsequently recruited additional 83 individuals: 25 with
TB, 36 with LTBI and 22 with HC to further validate the
microarray results using the same genes of interest above. As high
as 81% of selected genes were confirmed by qPCR, which
displayed the same regulation patterns as microarray study (Table
S2). Genes with significantly differential expression among
corresponding comparisons were shown in bold in Table S2
(Mann-Whitney U test, P value ,0.05). Among these genes, IFN-
c, CXCL10, IL2 and CXCL11 exhibited statistically significant
difference with P value ,0.001 and ratio .2 in the comparisons of
TB vs. HC, TB&LTBI vs. HC, and TB vs. LTBI&HC. Five genes
(CXCL10, ATP10A, TLR6, IL2RA, and FLNB) were differen-
tially expressed between TB and LTBI group and the fold changes
of them in PPD-stimulated PBMCs from TB patients were greater
than those from the LTBI individuals (Table S2). Scatter plots
of four genes with P value ,0.01 (CXCL10, ATP10A, TLR6,
IL2RA) were shown in Figure 3.
Identification of biomarkers to distinguish TB from LTBI
Both T-SPOT.TB and QuantiFERON-TB Gold In-tube assays
that detect antigen specific IFN-c release cannot discriminate TB
patients from individuals with latent infection [15]. Our study also
indicated that the expression levels of IFN-c was not significantly
different between TB and LTBIbyqPCR (Pvalue =0.07;TableS2).
Thus, we attempted to discover whether multiple genes possessed
better predictive power than any single gene in discriminating TB
from LTBI.
Receiver operating characteristic (ROC) methodology was
applied to evaluate the discriminatory ability of five differentially
expressed genes (CXCL10, ATP10A, TLR6, IL2RA, and FLNB)
between TB and LTBI in microarray validation study. The values
of area under curve (AUC) of these genes are shown in Table 4.
Thereafter, we subjected these five genes to decision tree analysis
to find ideal gene combination and to optimize the discrimination
between TB and LTBI using R program with 15-fold cross-
validation. This analysis demonstrated that a combination of
CXCL10, ATP10A and TLR6 provided the best predictive
capacity, with as many as 85% individuals being correctly
classified (Figure 4). The sensitivity of this three-gene combination
was 80%, as 20 of 25 TB patients were correctly identified; and the
specificity was 89%, as only 4 of 36 LTBI individuals were
incorrectly identified as active TB.
We subsequently validated the diagnostic ability of this
combination to identify TB patients from individuals with MTB
infection in 36 subjects (TB=17, LTBI=19), whose clinical status
was unknown to the investigators. The expression of three
biomarkers of interest was examined by the same procedure as
above. It turned out that there was significant difference of these
three genes between TB and LTBI (Table S2). The ROC results
were shown in Table 4. According to the optimal cutoff yielded by
the decision tree analysis, the combination of CXCL10, ATP10A
and TLR6 could correctly classify 81% individuals, with a
sensitivity of 71%, specificity of 89%, positive predictive value of
86% and negative predictive value of 77% (Figure S1).
Discussion
The human immune response to MTB infection is highly
complex and multifaceted. Identifying the immunologic charac-
teristics in different infectious status will facilitate development of
interventions to control initial infection and prevent reactivation of
latent infection. In this study, we described the global gene
expression differences in TB, LTBI and HC, and identified distinct
transcriptional signatures of tuberculosis infection and active
disease. Most importantly, we found that the combination of
CXCL10, ATP10A and TLR6 could be used as novel biomarkers
to differentiate TB from LTBI.
Unlike most previous microarray studies on TB using non-
stimulated whole blood [22,23,25], the present work examined
transcriptional profiles using PPD-stimulated PBMCs to concen-
trate on detecting changes in immune response specific to MTB
infection and therefore to identify TB-specific gene expression
changes. To our knowledge, this is the first study using MTB-
specific antigens as stimulus to activate PBMCs which are known
to contain both monocytes and lymphocytes needed for recalling
immune response and elucidate the complex immune responses
present in different status of TB infection. PPD as a mixture of
MTB antigens widely used in skin test, could stimulate more
comprehensive cytokines spectrum than ESAT-6/CFP-10 used in
IFN-c release assays [20]. Therefore, the stimulation of PPD could
provoke more diverse TB-specific immune responses than ESAT-
6/CFP-10, allowing potentially more comprehensive immune
Table 3. Significantly regulated genes in PPD-stimulated
PBMCs unique for tuberculosis infection and active disease
with ratio .4.
GeneSymbol Means Ratio Regulation t-test
TB&LTBI/HC TB&LTBI HC P value
IL2 96.54 5.65 17.09 up 0.0005
CXCL9 10.39 1.32 7.86 up 0.0061
IFNG 13.17 1.76 7.49 up 0.0006
CXCL10 4.67 0.77 6.05 up 0.0096
CXCL11 3.81 0.65 5.85 up 0.0400
CCL8 3.89 0.70 5.57 up 0.0199
BATF2 4.05 0.84 4.80 up 0.0029
TB/LTBI&HC TB LTBI&HC P value
BX090755 0.10 0.98 10.13 down 0.0050
IFNG 24.46 3.53 6.93 up 0.0014
UBD 8.01 1.38 5.81 up 0.0126
CXCL11 6.64 1.19 5.58 up 0.0474
CXCL9 16.42 2.95 5.57 up 0.0333
CXCL10 7.48 1.50 4.99 up 0.0267
RSPO3 1.76 0.36 4.85 up 0.0208
CCL8 6.22 1.30 4.77 up 0.0397
DB513559 0.09 0.37 4.38 down 0.0110
HMGA2 4.97 1.22 4.06 up 0.0001
doi:10.1371/journal.pone.0024290.t003
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TB and LTBI.
The individuals recruited were from BCG-vaccinated popula-
tions. Therefore, the LTBI individuals were defined as positive
IGRAs test, independent of TST results [26]. In order to
concentrate on detecting the immunological difference in response
to MTB infection, we recruited healthy donors from the family
members who lived together with the TB patients [23]. We also
chose a relatively short stimulation time (t=4 hours) to minimize
the influence of other factors on PBMCs activation, in order to
enhance the detection of genes expressed in early immune
response to MTB-specific antigens [27,28].
In the pair-wise comparisons, TB patients displayed the most
pronounced difference compared with individuals from LTBI and
HC. Functional annotation revealed that genes involved in response
to external stimulus were enriched in all three pair-wise compar-
isons, which indicated that variance in the early behavior of PBMCs
in response to PPD might contribute to the later immune
consequence. In addition, several studies have been performed on
the individuals with MTB infection to identify gene expression
profiles [22,23,25]. Genes in the categories of chemotaxis, cell
communication, signal transduction, inflammatory response and
protein binding were identified in comparisons of TB vs. LTBI and
TB vs. HC [23,25], which is consistent with our data (Table S1).
Maertzdorf et al suggested the importance of apoptosis regulation
and human defense responses in the susceptibility and resistance to
TB, the latter of which also exhibited significance in our study
(Table S1). However, FCGR1B, identified as the most differentially
expressed gene between TB and LTBI in also Maertzdorf’s study,
wasnot proven in our studyas P value was0.79. In another study by
O’Garra and colleagues, a neutrophil-driven IFN (both IFN-c and
type I IFN-ab)-inducible gene profile was identified as TB-specific
signature [22]. Similarly, our data showed that signaling pathway of
IFN-c displayed significant difference with a corrected P value
=0.0032 in the comparison between TB and LTBI, implicating its
crucial role in immune response against MTB infection.
In the multivariate analysis, despite IL2RA exhibiting signifi-
cant difference in expression between TB and LTBI by qPCR (P
value =0.0073), it was excluded from the final diagnostic
combination of CXCL10, ATP10A and TLR6. Spearman
correlation analysis revealed that the correlation of expression
between IL2RA and CXCL10 was significant with R=0.63 and P
value ,0.0001, indicating their close association and similarity in
expression pattern for both LTBI and TB conditions, and
therefore inclusion of IL2RA into the diagnostic combination is
unlikely to improve the discriminative power of the test any
further. Eventually, the measurement of PPD-stimulated changes
in mRNA levels for CXCL10, ATP10A and TLR6 was validated
as the best predictor distinguishing TB from LTBI, with 71%
sensitivity, 89% specificity, and 81% of individuals correctly
classified. Its discriminative capacity was comparable to single-
positive TNF-a MTB-specific CD4
+ T cells or the combination of
Figure 3. Scatter plots of four discriminatively expressed genes between TB and LTBI by qPCR with P value ,0.01. Horizontal bar,
median fold change of each group following PPD stimulation. ** significant difference: 0.001, P value ,0.01.
doi:10.1371/journal.pone.0024290.g003
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that this three-gene panel possesses the capacity to serve as novel
diagnostic biomarkers separating TB from LTBI.
In microarray validation study, there were four genes exhibiting
remarkable difference in TB group compared with LTBI group
with P value ,0.01: ATP10A, CXCL10, TLR6 and IL2RA.
ATP10A belonged to the family of P-type cation transport
ATPases with a well-defined phosphorylation domain [30] and
subfamily of aminophospholipid-transporting ATPases [31].
ATP10A was suggested to be imprinted and associated with type
2 diabetes [32]. Though other ATPases such as ATP1B3,
ATP8B2, and ATP6V0E1 were reported to be differentially
expressed genes between TB patients and LTBI individuals in the
O’Garra study [22], ATP10A was for the first time found as a
differentially expressed gene which was more repressed in TB
patients than in LTBI individuals upon PPD stimulation (Table
S2). ATP10A was reported to play roles in transmembrane
movement of small molecules, but whether this function is related
with TB susceptibility and resistance remains tentative.
CXCL10, also known as IP-10 (IFN-c-induced-protein 10), is a
CXC chemokine produced by several cell types such as monocytes
and T cells, and is located on chromosome 4 in a cluster with
CXCL9 and CXCL11. In the current study, the expression levels
of these three genes (CXCL9, CXCL10 and CXCL11) did show a
notable consistency (Table 2, 3). The binding of CXCL10 to
receptor CXCR3 can contribute to pleiotropic effects, including
stimulation of monocytes, natural killer and T-cell migration and
modulation of adhesion molecule expression [33,34]. Expression
of CXCL10 has been reported in many Th1-type inflammatory
diseases, through recruiting monocytes and activating T-cells into
sites with tissue inflammation [35]. In addition, elevated levels of
CXCL10 have been reported in plasma and infection foci in
individuals infected with MTB [36,37]. As a potential marker for
the diagnosis of MTB infection, CXCL10 had been used to
Table 4. ROC analysis of selected genes for discrimination between TB group and LTBI group.
Gene AUC P value %Sensitivity %Specificity Sum
Microarray validation set (n=61)
ATP10A 0.74 0.0019 72 64 1.36
CXCL10 0.72 0.0045 88 64 1.52
TLR6 0.70 0.0099 88 50 1.38
IL2RA 0.70 0.0073 72 78 1.50
FLNB 0.71 0.0442 64 72 1.36
Biomarker validation set (n=36)
ATP10A 0.72 0.0235 59 79 1.38
CXCL10 0.85 0.0004 65 95 1.59
TLR6 0.79 0.0034 76 74 1.50
ROC, receiver operating characteristic; AUC, area under curve; Sum, the sum of sensitivity and specificity.
doi:10.1371/journal.pone.0024290.t004
Figure 4. The combination of CXCL10, ATP10A and TLR6 provides the best discrimination between TB patients and LTBI
individuals. The sensitivity and specificity of this three-gene panel was 80% and 89% respectively. 85% individuals were correctly classified. TB
group, n=25; LTBI group, n=36. Rectangle: internal nodes; Oval and hexagon: terminal nodes showing the number finally determined as TB and
LTBI, respectively.
doi:10.1371/journal.pone.0024290.g004
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performance in distingushing between TB and LTBI. Here in our
study, CXCL10 exhibited good diagnostic power in discriminating
TB from LTBI (Table 4). Its expression was highly up-regulated by
PPD in TB patients, but not in individuals with LTBI in our
microarray and biomarker validation study (Table S2). This strong
up-regulation of CXCL10 in PPD-stimulated PBMCs from TB
patients may reflect its active role in the inflammatory process
involved in TB pathogenesis.
TLR6 variant was documented to contribute to human
susceptibility to TB [39] and was up-regulated in fresh unstimulated
whole blood of patients with active pulmonary TB (n=10)
compared with healthy donors [40]. In contrast, our data showed
that TLR6 expression in PBMCs was down-regulated by PPD in
TB patients whereas almost no change in LTBI individuals (Table
S2). Such variance may result from the use of the stimulus of the
specific antigens and needs to be further validated within a larger
number of samples. Heterodimers of TLR2 with TLR6 have been
reported to be responsible for the recognition of soluble factors of
MTB [41], and this ligation of TLRs may trigger either MyD88-
dependent or MyD88-independent pathways involving in the
initiation of T-cell mediated immunity [42]. Given the important
role of TLRs in innate immunity and initiation of adaptive immune
response, the diverse regulation pattern of TLR6 expression in TB
and LTBI was likely to be a factor responsible for the different
clinical outcome following MTB infection, which needs to be future
investigated.
IL2RA, also known as CD25, is the alpha chain of the IL2
receptor which is present on activated T cells and B cells [43,44].
Antigen binding to the T cell receptor (TCR) stimulates the
expression of IL2 and IL2R, which can subsequently stimulate the
growth, differentiation and survival of antigen-selected cytotoxic T
cells [45,46,47]. This feature may favor the elimination of
intracellular MTB. IL2RA is also surface marker of regulatory T
cells (Tregs). It was reported that Tregs could inhibit Th1
responses and its frequency was high in active tuberculosis
compared with uninfected donors and individuals with latent
infection [48,49]. In our study, the expression level of IL2RA
induced by PPD was also higher in TB than that in LTBI group.
In summary, we analyzed comprehensive gene expression
patterns associated with different MTB infectious status, and
confirmed that the combinations of CXCL10, ATP10A, and
TLR6 could be used as reliable predictor for active TB. These
findings would not only have important implications for
developing novel diagnostic biomarkers to differentiate active
disease from LTBI, but also shed light on immune mechanisms
underlying human staying latency or progression to active disease
after infection with MTB and the immunological determinants
promoting this transformation.
Materials and Methods
Human subjects
Patients with active TB were diagnosed based on the following
criteria: clinical signs and symptoms including fever, cough and
productive sputum; a suggestive chest X-ray; positive Ziehl-
Neelsen stain for acid-fast bacilli or positive culture for MTB in
sputum. In order to avoid the influence of anti-TB treatment,
patients who received directly observed short-course therapy
(DOTS) more than 4 weeks were excluded. Patients with allergic
diseases, diabetes, cancer, immune-compromised conditions, and
co-infections with HBV were also excluded. LTBI subjects were
recruited from close contacts of active TB patients, with positive
T-SPOT.TB test (Oxford Immunotech, UK), negative chest
radiograph and no clinical symptoms or evidence of active TB
[26,50]. Healthy controls were also recruited from family members
[23] of patients with negative T-SPOT.TB test, no clinical
evidence of TB and normal chest radiography. All subjects were
.14 years of age and HIV-negative.
In the microarray study, twelve subjects were enrolled with
three groups: TB (n=4), LTBI (n=4) and HC (n=4). The qPCR
validation study for microarray experiments enrolled 83 subjects
including 25 TB patients, 36 LTBI individuals and 22 healthy
controls, which is designated as ‘microarray validation set’. In
order to estimate the diagnostic power of the three biomarkers,
another validation set, termed as ‘biomarker validation set’, was
recruited with 17 TB patients and 19 LTBI subjects. TB patients
were recruited from Pulmonary Hospital in Chongqing, China.
The demographic characteristics of the study populations were
described in Table 5. The study was approved with written
consent by the Ethics Committee of Huashan Hospital, Fudan
University, and written informed consent was obtained from all
the participants.
Table 5. The demographic characteristics of the study
populations.
Study groups TB LTBI HC
Microarray set(n=12)
N u m b e r o f s u b j e c t s 444
Age years(median) 30(22–68) 37(19–53) 30(14–48)
Gender (male/female) 2/2 2/2 1/3
BCG vaccination Yes 3 4 4
N o 000
Not known 1 0 0
TST + 240
2 104
Not known 1 0 0
Microarray validation
set(n=83)
Number of subjects 25 36 22
Age years(median) 41(16–86) 50(14–83) 46(14–77)
Gender (male/female) 16/9 13/23 7/15
BCG vaccination Yes 16 29 17
N o 753
Not known 2 2 2
TST + 10 26 11
2 622
Not known 9 8 9
Biomarker validation
set(n=36)
Number of subjects 17 19
Age years(median) 47(21–84) 52(30–76)
Gender (male/female) 13/4 8/11
BCG vaccination Yes 13 16
No 1 1
Not known 3 2
TST + 12 11
2 05
Not known 5 3
doi:10.1371/journal.pone.0024290.t005
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Peripheral blood (4ml) was withdrawn from median cubital vein
of the antecubital fossa from each participant in heparinized
vacutainer tubes (Becton Dickinson). PBMCs were separated by
density gradient using Lympholyte Cell Separation Media
(CEDARLAN, Canada) within 6 hours of blood withdrawal.
The number of trypan blue-stained cells was counted using
CountessH Automated Cell Counter (Invitrogen, USA). PBMCs
from each subject were divided into two portions and cultured
with AIM-V (Invitrogen Life Technologies, USA) containing
2 mM L-glutamine, 50 mg/ml streptomycin sulfate, 10 mg/ml
gentamicin sulfate, and stimulated with or without 10 mg/ml
Mycobacterium tuberculosis purified protein derivative (PPD, Mycos
Research LLC, Loveland, CO, Colorado, USA) for 4 hours before
RNA extraction.
RNA extraction
Total RNA was extracted from PBMCs using TRIzol reagent
(Invitrogen Life Technologies) according to the protocols recom-
mended by the manufacturer. RNase-free DNase I (Invitrogen
Life Technologies) was used to remove genomic DNA contami-
nation. The integrity and quality of RNA was evaluated by Agilent
2100 Bioanalyzer (Agilent Technologies). RNA with a 2100 RIN
(RNA integrity number) $7.0 and 28S/18S .0.7 was used for the
microarray study.
Microarray hybridization and data processing
Microarray hybridization, scanning, and standardization were
performed in Shanghai Biochip Co., Ltd using Agilent’s Whole
Human Genome Oligo Microarray (Agilent Technologies) which
contains about 41,000 genes and transcripts. A two-color (Cy3 and
Cy5) hybridization format was used for the microarray. RNA
extracted from PPD-stimulated PBMCs was labeled with Cy3
(Cy3-dCTP), whereas the one from non-stimulated PBMCs was
labeled with Cy5 (Cy5-dCTP). cDNA synthesis was carried out
using the Agilent Fluorescent Direct Label kit according to the
manufacturer’s instructions. The cDNA samples with and without
PPD stimulation from each individual were hybridized to the same
slide [51]. The labeling and hybridization were performed
according to protocols from the manufacturer [52,53]. The signals
were scanned using Agilent G2565BA microarray scanner and
normalized before analysis. All the microarray data was MIAME
compliant and had been deposited in GEO database with
accession number: GSE27984.
Quantitative real-time PCR analysis
Purified RNA was reverse transcribed to cDNA using Prime-
ScriptH RT reagent Kit (TaKaRa) according to the manufacturer’s
protocol. qPCR was performed using SYBR
TM Green PCR Master
Mix (TaKaRa) following standard conditions. PCR amplification
was conducted in ABI 7500 Real-time PCR System (Applied
Biosystems, Inc). The relative amount of expressed RNA was
calculated by comparison with the expression of the housekeeping
gene GAPDH using the 2
2ggCt method [54].
Data analysis
In the microarray study, the fold change of gene expression level
altered by PPD stimulation was expressed as log2 transformed
Cy3/Cy5 intensities for each probe. Differentially expressed genes
were identified based on the P values ,0.05 by Student’s t-test and
the fold change .2.0. Unsupervised two-way hierarchical
clustering was performed to analyze gene expression patterns of
multiple genes simultaneously in 12 subjects [22]. Gene Ontology
(GO) analysis was applied to functional analysis of differentially
expressed genes using GeneSpring software. The database was
downloaded from the website of Gene Ontology (http://www.
geneontology.org). The significance of the association between the
genes and GO terms was measured by P value calculated by
hypergeometric test. Benjamin–Hochberg correction was used for
multiple GO term testing and the correlation between them
(corrected P value). The above statistical analyses were performed
using GeneSpring GX version 11.0 (Agilent Technologies).
In the qPCR study, Mann-Whitney U test was used to compare
gene expression levels among groups using SPSS 16.0 software
(SPSS Company, Chicago, IL) and difference was considered
significant when P value was ,0.05. ROC analysis was performed
to determine the discriminative ability of selected genes to
distinguish TB from LTBI with the overall accuracy assessed by
AUC values [55]. Combinations of markers were identified by
decision tree analysis via R 2.12.1 (R Foundation for Statistical
Computing). Using this algorithm, the best tree was chosen as
previous study [21].
Supporting Information
Figure S1 Combination of CXCL10, ATP10A and TLR6 could
distinguish TB patients and LTBI individuals. The sensitivity and
specificity of this three-gene panel was 71% and 89% respectively.
81% individuals were correctly classified. TB group, n=17; LTBI
group, n=19. Rectangle: internal nodes; Oval and hexagon:
terminal nodes showing the number finally determined as TB and
LTBI, respectively.
(TIF)
Table S1 GO analysis of differentially expressed genes.
(XLS)
Table S2 Validation results of 30 differentially expressed genes
in pair-wise comparisons and 22 genes specific for tuberculosis
infection and active disease in 83 subjects by qPCR.
(XLS)
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